Isabel Gomez-Orellana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabel Gomez-Orellana has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Duncan R Paton
Emisphere Technologies, Inc., 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
2 shared publicationsBruce Varinano
Emisphere Technologies, Inc., 15 Skyline Drive, Hawthorne, New York 10532
1 shared publicationDuncan R. Paton
Emisphere Technologies, Inc., 15 Skyline Drive, Hawthorne, New York 10532
1 shared publication- Ehud Arbit
Emisphere Technologies, Tarrytown, NY, USA
1 shared publication Judy Miura‐Fraboni
Emisphere Technologies, Inc., 15 Skyline Drive, Hawthorne, New York 10532
1 shared publication- Michael Goldberg
Emisphere Technologies Inc. 765 Old Saw Mill River Road. Tarrytown, NY 10591, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2006
- Published by Springer Nature in Thrombosis Journal
- Vol. 4 (1) , 6
Oral heparin: status review
Unfractionated heparin and low molecular weight heparin are the most commonly used antithrombotic and thromboprophylactic agents in hospital practice. Extended out-of-hospital treatment is inconvenient in that these agents must be administered parenterally. Current research is directed at development of a safe and effective oral antithrombotic agent as an alternative for the effective, yet difficult to use vitamin K antagonists. A novel drug delivery technology that facilitates transport of drugs across the gastrointestinal epithelium has been harnessed to develop an oral dosage form of unfractionated heparin. Combining unfractionated heparin with the carrier molecule, sodium N-(8 [2-hydroxybenzoyl]amino) caprylate, or SNAC has markedly increased the gastrointestinal absorption of this drug. Preclinical and clinical studies to-date suggests that oral heparin-SNAC can confer a clinical efficacious effect; further confirmation is sought in planned clinical trials.
- 1 January 2006
- Published by Springer Nature in Thrombosis Journal
- Vol. 4 (1) , 6
Open AccessOral heparin: status review
Unfractionated heparin and low molecular weight heparin are the most commonly used antithrombotic and thromboprophylactic agents in hospital practice. Extended out-of-hospital treatment is inconvenient in that these agents must be administered parenterally. Current research is directed at development of a safe and effective oral antithrombotic agent as an alternative for the effective, yet difficult to use vitamin K antagonists. A novel drug delivery technology that facilitates transport of drugs across the gastrointestinal epithelium has been harnessed to develop an oral dosage form of unfractionated heparin. Combining unfractionated heparin with the carrier molecule, sodium N-(8 [2-hydroxybenzoyl]amino) caprylate, or SNAC has markedly increased the gastrointestinal absorption of this drug. Preclinical and clinical studies to-date suggests that oral heparin-SNAC can confer a clinical efficacious effect; further confirmation is sought in planned clinical trials.
- 10 May 2005
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 2 (3) , 419-433
Strategies to improve oral drug bioavailability
Efforts to improve oral drug bioavailability have grown in parallel with the pharmaceutical industry. As the number and chemical diversity of drugs has increased, new strategies have been required to develop orally active therapeutics. The past two decades have been characterised by an increased understanding of the causes of low bioavailability and a great deal of innovation in oral drug delivery technologies, marked by an unprecedented growth of the drug delivery industry. The advent of biotechnology and consequent proliferation of biopharmaceuticals have brought new challenges to the drug delivery field. In spite of the difficulties associated with developing oral forms of this type of therapeutics, significant progress has been made in the past few years, with some oral proteins, peptides and other macromolecules currently advancing through clinical trials. This article reviews the approaches that have been successfully applied to improve oral drug bioavailability, primarily, prodrug strategies, lead optimisation through medicinal chemistry and formulation design. Specific strategies to improve the oral bioavailability of biopharmaceuticals are also discussed.
- 10 May 2005
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 2 (3) , 419-433
Strategies to improve oral drug bioavailability
Efforts to improve oral drug bioavailability have grown in parallel with the pharmaceutical industry. As the number and chemical diversity of drugs has increased, new strategies have been required to develop orally active therapeutics. The past two decades have been characterised by an increased understanding of the causes of low bioavailability and a great deal of innovation in oral drug delivery technologies, marked by an unprecedented growth of the drug delivery industry. The advent of biotechnology and consequent proliferation of biopharmaceuticals have brought new challenges to the drug delivery field. In spite of the difficulties associated with developing oral forms of this type of therapeutics, significant progress has been made in the past few years, with some oral proteins, peptides and other macromolecules currently advancing through clinical trials. This article reviews the approaches that have been successfully applied to improve oral drug bioavailability, primarily, prodrug strategies, lead optimisation through medicinal chemistry and formulation design. Specific strategies to improve the oral bioavailability of biopharmaceuticals are also discussed.
- 1 March 1999
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (3) , 247-253
Advances in the oral delivery of proteins
The efforts to develop oral formulations of protein drugs have been intensified in recent years as a consequence of the increasing number of protein-based therapeutics that are being identified. Yet, due to the substantial and unprecedented challenges that the oral delivery of proteins presents, advances in this field have been relatively slow. Nonetheless, several oral formulations of proteins are already in clinical trials and others are expected to start clinical testing in the immediate future. This review discusses the recent developments and the patent literature in the area of oral delivery of protein therapeutics.
- 1 March 1999
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (3) , 247-253
Advances in the oral delivery of proteins
The efforts to develop oral formulations of protein drugs have been intensified in recent years as a consequence of the increasing number of protein-based therapeutics that are being identified. Yet, due to the substantial and unprecedented challenges that the oral delivery of proteins presents, advances in this field have been relatively slow. Nonetheless, several oral formulations of proteins are already in clinical trials and others are expected to start clinical testing in the immediate future. This review discusses the recent developments and the patent literature in the area of oral delivery of protein therapeutics.
- Open Access
- 1 June 1998
- Published by Wiley in Protein Science
- Vol. 7 (6) , 1352-1358
Thermodynamic characterization of an intermediate state of human growth hormone
The thermal denaturation of recombinant human growth hormone (rhGH) was studied by differential scanning calorimetry and circular dichroism spectroscopy (CD). The thermal unfolding is reversible only below pH 3.5, and under these conditions a single two-state transition was observed between 0 and 100°C. The magnitudes of the ΔH and ΔCP of this transition indicate that it corresponds to a partial unfolding of rhGH. This is also supported by CD data, which show that significant secondary structure remains after the unfolding. Above pH 3.5 the thermal denaturation is irreversible due to the aggregation of rhGH upon unfolding. This aggregation is prevented in aqueous solutions of alcohols such as n-propanol, 2-propanol, or 1,2-propanediol (propylene glycol), which suggests that the self-association of rhGH is caused by hydrophobic interactions. In addition, it was found that the native state of rhGH is stable in relatively high concentrations of propylene glycol (up to 45% v/v at pH 7-8 or 30% at pH 3) and that under these conditions the thermal unfolding is cooperative and corresponds to a transition from the native state to a partially folded state, as observed at acidic pH in the absence of alcohols. In higher concentrations of propylene glycol, the tertiary structure of rhGH is disrupted and the cooperativity of the unfolding decreases. Moreover, the CD and DSC data indicate that a partially folded intermediate with essentially native secondary structure and disordered tertiary structure becomes significantly populated in 70-80% propylene glycol.
- 1 June 1998
- Published by Wiley in Protein Science
- Vol. 7 (6) , 1352-1358
Open AccessThermodynamic characterization of an intermediate state of human growth hormone
The thermal denaturation of recombinant human growth hormone (rhGH) was studied by differential scanning calorimetry and circular dichroism spectroscopy (CD). The thermal unfolding is reversible only below pH 3.5, and under these conditions a single two-state transition was observed between 0 and 100°C. The magnitudes of the ΔH and ΔCP of this transition indicate that it corresponds to a partial unfolding of rhGH. This is also supported by CD data, which show that significant secondary structure remains after the unfolding. Above pH 3.5 the thermal denaturation is irreversible due to the aggregation of rhGH upon unfolding. This aggregation is prevented in aqueous solutions of alcohols such as n-propanol, 2-propanol, or 1,2-propanediol (propylene glycol), which suggests that the self-association of rhGH is caused by hydrophobic interactions. In addition, it was found that the native state of rhGH is stable in relatively high concentrations of propylene glycol (up to 45% v/v at pH 7-8 or 30% at pH 3) and that under these conditions the thermal unfolding is cooperative and corresponds to a transition from the native state to a partially folded state, as observed at acidic pH in the absence of alcohols. In higher concentrations of propylene glycol, the tertiary structure of rhGH is disrupted and the cooperativity of the unfolding decreases. Moreover, the CD and DSC data indicate that a partially folded intermediate with essentially native secondary structure and disordered tertiary structure becomes significantly populated in 70-80% propylene glycol.
- 1 March 1998
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 8 (3) , 223-234
Advances in the oral delivery of proteins
Due to their low oral bioavailability, most protein drugs are only available as parenteral formulations. The oral delivery of proteins is challenging and has often been considered an unattainable goal; nevertheless, the efforts to develop oral formulations of proteins continue to be numerous. The approaches devised to overcome the obstacles for the absorption of proteins from the gastrointestinal tract are various, and include the co-administration of enzyme inhibitors and/or absorption enhancers, the encapsulation in liposomes, microemulsions, or biodegradable particles, and the modification of proteins through the attachment of chemical moieties. This article reviews the recent patent literature related to formulation strategies to improve the oral bioavailablity of proteins.
- 1 March 1998
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 8 (3) , 223-234
Advances in the oral delivery of proteins
Due to their low oral bioavailability, most protein drugs are only available as parenteral formulations. The oral delivery of proteins is challenging and has often been considered an unattainable goal; nevertheless, the efforts to develop oral formulations of proteins continue to be numerous. The approaches devised to overcome the obstacles for the absorption of proteins from the gastrointestinal tract are various, and include the co-administration of enzyme inhibitors and/or absorption enhancers, the encapsulation in liposomes, microemulsions, or biodegradable particles, and the modification of proteins through the attachment of chemical moieties. This article reviews the recent patent literature related to formulation strategies to improve the oral bioavailablity of proteins.